Clarinex exclusivity
Executive Summary
Clarinex pediatric studies produce an additional six months of market exclusivity for the antihistamine. Schering-Plough submitted an NDA to FDA in December 2002 "seeking clearance to market Clarinex Syrup for children between the ages of six months and two years," the company said. Clarinex is approved for patients 12 and older. Schering's exclusivity for Clarinex now runs until June 21, 2007...